Introduction: Neoadjuvant treatment might increase resectability of thymic epithelial tumors (TETs). No standardized pathologic grading scheme for tumor response is available. Also, it is unclear whether radiologic treatment response can predict pathologic response.
Results: A total of 49 patients, including 29 men, with a median age of 47.6 years and thymomas (n ¼ 28) or thymic carcinomas (n ¼ 21) were included. In five cases, pretreatment tumor type differed from posttreatment diagnosis. Thymic carcinomas had a greater morphologic response to neoadjuvant treatment than did thymomas with a lower percent viable tumor (p < 0.0001) and lower TRG (p<0.0001). Agreement for TRG by three reviewers was good (Krippendorff a ¼ 0.838). By imaging (n ¼ 24), partial response and larger reduction in tumor longest diameter and volume were associated with lower TRG (p ¼ 0.0093, p ¼ 0.0042, and p ¼ 0.0021, respectively) and lower percent viable tumor (p ¼ 0.0041, p ¼ 0.0034, and p ¼0.0019). TRG correlated with radiologic change in tumor longest diameter and volume (Spearman correlation coefficient ¼ 0.59 and 0.61, respectively). Radiologic change in tumor longest diameter and volume reasonably predicted pathologic TRG of 3 to 5 versus 1 or 2 (area under the curve 0.73 and 0.71, respectively). Sixty-seven percent of patients' tumors were completely resected.
Introduction
Complete resection has been shown to be a prognostic parameter for thymic epithelial tumors (TETs) in most studies. [1] [2] [3] [4] Resectability of TETs usually depends on stage and size of the tumor. 1, 3 Complete resection rates range between 100% for Masaoka stage I tumors and 0% to 78% for stage IV tumors. 3 Neoadjuvant treatment increases the resectability of otherwise unresectable or not completely resectable TETs. In fact, complete resection rates have been reported as being between 57% and 80% after chemotherapy, [5] [6] [7] [8] [9] 90.5% after radiation therapy 9 and 77% and 80% after chemoradiation. 10, 11 In general, however, such studies are small.
Only a few studies have reviewed histologic features of TETs subsequent to neoadjuvant treatment. 7, [9] [10] [11] [12] [13] [14] [15] These studies show 0% to 100% and 1% to 95% viable tumor in thymomas and thymic carcinomas after neoadjuvant therapy, respectively. Complete pathologic response is reported in 0% to 31% of thymomas but not in thymic carcinomas. The study by Weissferdt and Moran 12 found variable amounts of necrosis, proliferation of histiocytes, hemorrhage, calcifications, cholesterol granulomas, and cystic changes within thymomas resected after neoadjuvant chemotherapy. Differences in the histologic subtype of pre-and post-neoadjuvant radiation specimens have also been described. 9 A pathologic grading scheme for tumor response to neoadjuvant treatment has not been investigated in TETs. Moreover, currently there is no guidance for the assessment of pathologic treatment response in these tumors. Such a grading scheme for tumor regression should be simple and reproducible. A reproducible grading scheme would (1) be important for standardized pathology reporting, (2) assist the oncologist in treatment decisions, and (3) facilitate multi-institutional studies. Grading schemes for tumor regression after neoadjuvant treatment are already used in routine pathology practice for multiple other organ systems. 16 If considered unresectable, TETs are commonly treated with chemotherapy or chemoradiation followed by surgical resection. Therefore, such a grading scheme is greatly needed.
Although radiologic and pathologic response to neoadjuvant treatment in TETs has been studied independently, these treatment responses have not been compared and correlated. It is currently not clear whether radiologic response to neoadjuvant treatment can predict pathologic response and which radiologic parameter(s) might help to predict pathologic response in TETs. This information would be of importance to guide further treatment and to potentially predict outcome.
We have studied the pathologic response of TETs to neoadjuvant treatment. We have proposed a pathologic treatment response grading system to standardize reporting of such treatment effect. Moreover, we have correlated radiologic and pathologic response of TETs to neoadjuvant treatment.
Material and Methods

Patients
Patients with TETs that were considered unresectable and who underwent neoadjuvant chemotherapy, chemoradiation, or radiation therapy followed by surgical exploration at the Mayo Clinic Rochester and had a post-neoadjuvant treatment specimen for histopathologic review available were included in this study. Medical records were studied. Tumors were staged according to the modified Masaoka staging system 17 and the staging system that was recently proposed by the International Association for the Study of Lung Cancer (IASLC) and the International Thymic Malignancy Interest Group (ITMIG) (proposed IASLC/ITMIG staging). 18 Because most cases lacked lymph nodes for evaluation, the proposed IASLC/ITMIG staging could be used for only a minority of cases. Therefore, the T component of the proposed IASLC/ITMIG staging was used separately for some analysis. The study was approved by the Mayo Clinic Rochester Institutional Review Board (08-003478).
Pathology Review
Because of interobserver variability in the morphologic classification of TETs, 19 all pre-and postneoadjuvant treatment specimens were reviewed by three thoracic pathologists (A. C. R., M. C. A., and E. S. Y.). TETs were classified according to the current WHO classification. 20 If the reviewers disagreed, the WHO type that had been identified by the majority of the reviewers was chosen for further studies. Although it is not our practice to type thymomas on the basis of biopsy specimens because of their potential heterogeneity, for the purpose of this study we attempted to type thymomas on biopsies. Two cases were diagnosed as thymic carcinoma on the basis of pretreatment biopsy specimens, whereas the posttreatment specimens were classified as WHO type B2 or B3 thymoma with a minor component of thymic carcinoma. These two cases were classified as thymic carcinoma for all analyses.
All reviewers scored the pretreatment biopsy specimens and posttreatment surgical specimens for percent lymphocytes in the sum of lymphocytes and tumor cells. All posttreatment specimens were scored by all three reviewers for percent necrosis and percent viable tumor on the basis of the entire tumor bed and for tumor response grade (TRG). For statistical analysis, the mean percent lymphocytes, mean percent viable tumor, and mean percent necrosis identified by the reviewers were used. The TRG was based on the TRG proposed by Mandard et al. 16 and is summarized in Table 1 and shown in Figure 1 . If there was disagreement as to TRG, the mean TRG score of all reviewers was used unless otherwise noted. Histologic features that might be suggestive of treatment response similar to that in the study by Weissferdt and Moran, 12 including presence of cystic changes, necrosis, hemorrhage, foamy histiocytes, calcifications, and cholesterol clefts, were noted. In addition, we recorded fibrosis, focal large cells, clear cell features, and granulomatous reaction.
Image Analysis
If available, pre-and post-neoadjuvant treatment imaging studies were reviewed by two thoracic radiologists (G. B. J. and C. W. K.) blinded to the medical records, including imaging reports and results of the pathology review. Two computed tomography (CT) scans at specific time points were retrospectively identified for each patient reviewed. These CT scans were performed (1) immediately before neoadjuvant therapy and (2) after neoadjuvant therapy but immediately before surgery. If other thoracic imaging before the date of surgery was available in the medical record it was also reviewed by the radiologists. CT examinations were evaluated on an OsiriX (version 6.0.2 64-bit) workstation (Pixmeo SRL, Switzerland). On the CT images, regions of interest were drawn around the identified tumors on axial images by using the closed polygon tool. A volume of interest was then calculated by using the region of interest volume tool. The percentage change in the tumor's longest diameter and volume were calculated. Response Evaluation Criteria in Solid Tumors (RECIST), v1.1, 21 with the Byrne modification 22 were applied as recently proposed by ITMIG. 23 Additional specific qualitative evaluations were recorded; they included tumor shape and appearance, associated findings, and invasive features similar to those previously described. 24 Measurements were performed by consensus, and in some cases, measurements were averaged.
Statistical Analysis
Patient and tumor characteristics were summarized with medians and ranges for continuous data and with frequencies and percentages for categorical data. Overall survival (OS) and disease-free survival at 5 years after the surgical procedure were estimated with the KaplanMeier method. The interrater reliability between the three reviewers for rating the TRG was assessed with Krippendorff's a, which is similar to a weighted k for more than two raters. 25 Data were compared between patients with thymoma and those with thymic carcinoma by using Fisher's exact tests for categorical features and with Wilcoxon rank sum tests for continuous features. Associations between histopathologic response measures (TRG, percent viable tumor, and percent necrosis) and radiologic response measures (change in tumor volume and change in tumor longest diameter) were assessed with Spearman correlations. These histopathologic features were also compared between those with a partial response and those with stable disease by using Wilcoxon rank sum tests. Additionally, radiologic changes in a tumor's longest diameter and volume were dichotomized around the approximate overall median (<25% versus !25% decrease in tumor longest diameter and <60% versus !60% decrease in tumor volume) and the histopathologic measures were compared between these groups with Wilcoxon rank sum tests. Analyses were performed on all specimens combined, and they were also stratified by thymoma versus thymic carcinoma. The degree to which change in longest diameter or volume discriminates between a TRG of 1 or 2 versus 3 to 5 was assessed by calculating the area under the curve using logistic regression. p Values less than 0.05 were considered statistically significant. All analyses were performed using SAS version 9 (SAS Institute, InNc., Cary, NC) or R (R Foundation for Statistical Computing, Vienna, Austria). 26 
Results
Patient Characteristics
A total of 49 patients, including 29 men (59.2%), were included in the study. The median age of the patients at time of surgery was 47.6 years (range 25.0-77.2). Clinical and tumor characteristics are summarized in Table 2 . Follow-up data were available in all cases and are presented in Table 2 . One patient died on the day of surgery as a result of hemorrhage. Neoadjuvant treatment included chemotherapy, radiation, or chemoradiation. Details of the individual treatment regimens are compiled in Supplementary Data 1.
The median pathologic tumor size in completely resected tumors was 6.2 cm (range 0-23.0). A median of 1.1 slides per cm of tumor (range 0.08-14.6) were available for review. In cases without residual viable tumor, a median of 12 slides (range 7-16) were reviewed.
Thymic Carcinomas Had Better Pathologic Response to Neoadjuvant Treatment Than Thymomas
Histologic features of TETs after treatment are demonstrated in Tables 1 and 2 . Overall, approximately one-third of patients (16 of 49 [32.7%]) had no definite morphologic response to treatment (TRG 5), whereas three (6.1%) had a complete response with no residual tumor identified (TRG 1). Thymic carcinomas had greater treatment response with a lower percent viable tumor (median 20.0% versus 90.8%, p < 0.0001) and lower TRG (median 2.7 versus 4.7, p < 0.0001) than thymomas. When types A, AB, B1, and B2 thymomas were combined (n ¼ 17) and compared with type B3 thymomas (n ¼ 11), no significant differences were identified with respect to TRG (p ¼ 0.92), percent viable tumor (p ¼ 0.59), or percent tumor necrosis (p ¼ 0.26).
TRG and percent viable tumor significantly correlated with type of neoadjuvant treatment (p ¼ 0.0004 and Table 2 ). However, the overall number of patients was rather low. The morphologic classification of TETs in pretreatment biopsy specimens (n ¼ 27) and posttreatment specimens (n ¼ 49) and subtypes of thymic carcinoma are summarized in Table 2 .
In five cases pretreatment tumor type differed from posttreatment diagnosis (see Table 2 and Fig. 2 ). All five patients had been treated with chemotherapy.
Other posttreatment histologic features that might indicate treatment response are summarized in Table 2 and Figure 1 . On high magnification, large epithelioid cells with a high nuclear-to-cytoplasmic ratio and dark nuclear chromatin are growing in a desmoplastic stromal reaction consistent with poorly differentiated carcinoma (L). Post-neoadjuvant treatment complete resection specimen, on low magnification, shows a lobulated mass that predominantly comprises lymphocytes with scattered tumor cells (M) consistent with type B2 thymoma. However, there is a focus with features similar to those of the pretreatment biopsy specimen and suggestive of a minor component of poorly differentiated carcinoma (N and O). (P-T) A biopsy specimen shows clusters of epithelial cells associated with fibrosis (P and Q). Whereas two pathologists considered the findings to be indicative of thymic carcinoma, one pathologist favored type B3 thymoma. The incomplete resection specimen after neoadjuvant therapy revealed a lobulated mass (R) comprising bland (S) and focally more atypical cells with clear cytoplasm (T), with some growing as single-file and small cell nests within collagen fibrosis (S). These morphologic findings were considered type B3 thymoma (two pathologists, one of which thought that there is a minor component of thymic carcinoma) or thymic carcinoma (one pathologist). Hematoxylin and eosin-stained slides; original magnification, Â40 (A, D, F, I , and K), Â400 (B, C, E, G, J, L, O, Q, and T), Â20 (H and M), Â100 (N, P, and S), and Â12.5 (R).
carcinomas and most thymomas (78.6%) showed some degree of fibrosis in the posttreatment resection specimen (p ¼ 0.03).
TRG and percent viable tumor correlated with the T component of the recently proposed ITMIG/IASLC classification (p ¼ 0.0416 and p ¼ 0.0362, respectively) but not overall ITMIG/IASLC classification (p ¼ 0.29 and p ¼ 0.19, respectively). Tumors with a higher T stage had a lower TRG and lower percent viable tumor after neoadjuvant treatment (Fig. 3) 
The Pathologic Treatment Response Grade Was Reproducible
The overall agreement for TRG by the three reviewers was good (Krippendorff a ¼ 0.838). When all of the combinations of TRG ratings among the three reviewers for the 49 posttreatment specimens were considered, most (26 of 49 [53%]) were in complete agreement. When there was discordance, the difference was usually no more than one level ( ; only two of 49 specimens (4%) were discordant by a difference of two levels (three/four/five and two/four/four, respectively).
All Patients Had a Partial Radiologic Response or Stable Disease
Twenty-four patients, including 10 with thymomas and 14 with thymic carcinomas, had pre-and postneoadjuvant treatment CT imaging studies available. Radiologic findings are summarized in Table 2 . None of the patients with radiation alone had pre-and postneoadjuvant treatment imaging studies available. When RECIST, v1., were used, 11 patients had a partial response and 13 had stable disease. No patient had progressive disease or a complete radiologic response. Treatment (chemotherapy alone or chemoradiation) was not associated with partial response or stable disease (p ¼ 0.41). There was a strong correlation between changes in tumor longest diameter (the key component of RECIST) and changes in tumor volume after treatment (Spearman correlation coefficient ¼ 0.91). When types A, AB, B1, and B2 thymomas were combined (n ¼ 6) and compared with type B3 thymomas (n ¼ 4), no significant differences were identified with respect to RECIST (p ¼ 0.57).
Histopathologic and Radiologic Response to Neoadjuvant Treatment Correlated in Thymic Epithelial Tumors
Correlation between pathologic and radiologic response was studied in 24 cases with available pretreatment and posttreatment CT imaging studies. The results are shown in Table 3 When radiologic and pathologic responses were compared for thymomas and thymic carcinomas separately, partial radiologic response was associated with lower percent viable tumor (p ¼ 0.02) as well as with lower TRG (p ¼ 0.03) for thymic carcinomas. No other statistically significant findings were noted in the stratified analysis; however, the overall number of cases was relatively low for these categories.
All patients with complete pathologic response (TRG of 1) (n ¼ 3) had a partial radiologic response; all three patients with available CT images that did not show any pathologic response (TRG of 5) had stable radiologic disease (Fig. 4) . Area under the curve to measure how well the radiologic predictors (tumor longest diameter and volume) can discriminate between tumors with a TRG of 3 to 5 and those with a TRG of 1 or 2 show that both change in tumor longest diameter and change in tumor volume on CT images are reasonable (although not perfect) predictors of pathologic response (area under the curve ¼ 0.73 and 0.71, respectively).
None of the other imaging features evaluated on both pre-and post-neoadjuvant treatment CT scans, nor a change in these features between the two scans, were significantly associated with pathologic tumor response (data not shown). Such features included cyst/cavitation, tumor necrosis, calcification, heterogeneous density, blurring of the surrounding fat, abutment of greater than 50% diameter of a major vessel, tumor invading the superior vena cava, tumor invading other major vessels, elevated hemidiaphragm, pleural effusion, pleural nodules, pericardial effusion, pericardial nodules, adjacent lung changes, tumor feeding vessels with diameter greater than 5 mm, mediastinal adenopathy, and lobulated versus rounded tumor shape. However, the lack of significant association may be due in part to small sample size.
Complete Resection Was Achieved in Most Patients after Neoadjuvant Treatment
Complete resection was achieved in 33 of 49 patients (67.3%), including 15 of 22 (68.2%), nine of 13 (69.2%), and nine of 14 (64.3%) after chemotherapy, radiation or chemoradiation therapy, respectively. Incomplete resection was performed in four of 22 (18.2%), two of 13 (15.4%), and three of 14 (21.4%) patients after chemotherapy, radiation, or chemoradiation, respectively. Three of 22 (13.6%), two of 13 (15.4%) and two of 14 (14.3%) patients underwent biopsy only subsequent to chemotherapy, radiation, or chemoradiation, respectively, because the tumors were judged unresectable, usually on account of invasion into the myocardium or pulmonary artery (in two cases surgical reports were not available). Overall, patients who underwent complete resection had a significantly better OS (5-year OS ¼ 69.6%) than patients with incomplete resection (0%) or biopsy only (23.8%) (p ¼ 0.001). When OS was analyzed separately among patients with thymoma and those with thymic carcinoma, there was still a survival benefit for Radiologic decrease in tumor volume (dichotomized) <60% (n ¼ 10) patients with complete resection over patients who underwent incomplete resection or posttreatment biopsy only among patients with carcinoma (p ¼ 0.008), but the difference was not significant among patients with thymoma (p ¼ 0.10).
Discussion
Our study shows that more than two-thirds of TETs have a histologic response to neoadjuvant treatment. Furthermore, we propose a reproducible five-tier histopathologic TRG system for TET specimens that are resected after neoadjuvant therapy. Moreover, the histologic response is more pronounced in thymic carcinomas than in thymomas. Indeed, we found that both the percent viable tumor after neoadjuvant treatment and the TRG were significantly lower in thymic carcinomas than thymomas. In fact, three of 21 thymic carcinomas (14.3%) had a complete pathologic response and four of 21 (19.0%) had rare viable tumor cells. In contrast, a complete pathologic response was not observed in any thymoma, and only a single thymoma (type B3) of the 28 in our study (3.6%) had rare viable tumor cells. On the other hand, only a single thymic carcinoma of the 21 (4.8%) but 15 of the 28 thymomas (53.6%) had no pathologic response. Neoadjuvant therapy in general targets dividing cells. Therefore, it was not surprising that thymic carcinomas had the largest pathologic response to treatment given that thymic carcinomas usually have a higher mitotic activity than type B3 and A thymomas. 27 In addition, the Ki-67 labeling index of type B3 thymomas is in general slightly higher than that of type A thymomas, supporting our current finding that type B3 thymomas appear to be somewhat more receptive to neoadjuvant therapy than other thymomas. Furthermore, our study suggests that treatment response depends on the mode of neoadjuvant treatment. We found the best treatment response, with lowest TRG and percent viable tumor cells, after chemoradiation, whereas radiation had the least response to treatment. Although these findings were not statistically significant, if thymomas and thymic carcinomas were analyzed separately (likely because of the relatively low number of patients in each group), we observed similar trends.
Only a few studies have reviewed histologic features of TETs after neoadjuvant treatment. Eight such studies encompass a total of 146 patients with thymomas (n ¼ 131) or thymic carcinomas (n ¼ 15) of all stages. 7, [9] [10] [11] [12] [13] [14] The reported percent viable tumor after neoadjuvant treatment for both thymomas and thymic carcinomas has been quite variable. Indeed, these studies have shown 0% to 100% and 1% to 95% viable tumor in thymomas and thymic carcinomas, respectively. Complete pathologic response has been reported only in thymomas. Indeed, complete pathologic response has been described in up to 14.3% of patients with thymomas (three of 21) after radiation 9 and 0% to 31.2% after chemotherapy 7, [12] [13] [14] but not in patients treated with chemoradiation. 10 In our study, the median percent viable tumor was 90.8% for thymomas and 20.0% for thymic carcinomas within the reported ranges, but complete pathologic response was seen in only the thymic carcinomas. The cause for the differences in our study regarding occurrence of complete pathologic response to neoadjuvant treatment in thymomas versus in thymic carcinomas is not entirely clear but could have been due to variations in neoadjuvant treatment regimens. Sampling of the resected specimen might also have played a role; however, in our study we believed that cases with complete pathologic response were thoroughly sampled with a median of 12 slides per case.
Weissferdt and Moran reviewed histopathologic findings in 28 thymomas after neoadjuvant chemotherapy. 12 This study found necrosis (in 75% of cases), proliferation of histiocytes (in 75%), hemorrhage (in 54%), calcifications (in 29%), cholesterol granulomas (in 25%), cystic changes (in 21%), and fibrosis (percentage of cases not recorded) in treated thymomas. In our study, fibrosis was the most frequent histopathologic finding in post-neoadjuvant treatment TETs; it was present in all thymic carcinomas and 78.6% of thymomas. As in the study by Weissferdt and Moran, 12 we frequently identified foamy histiocytes and calcifications in thymomas and thymic carcinomas. We noted acute hemorrhage only in thymomas, not in thymic carcinomas. Necrosis, although present in 47.6% of thymic carcinomas, was rather infrequent in thymomas (in 14.3%) in our study. Furthermore, the percent necrosis per tumor bed area was overall relatively small and did not differ between thymomas and thymic carcinomas. In contrast to our study, Wright et al. 11 found 90% or higher amounts of necrosis in four of 10 Masaoka stage III and IVa thymic tumors after neoadjuvant chemoradiation. However, it is not entirely clear whether percent necrosis was determined on the basis of tumor bed area or viable tumor in that study. Regardless, as Weissferdt and Moran 12 already alluded to, none of the histologic features that were found in post-treatment TETs can be considered unique to treatment response because they can also be seen in nontreated TETs.
In general, it is thought that neoadjuvant therapy, at least in thymomas, might predominantly affect lymphocytes. In the study by Weissferdt and Moran, 12 tumor viability appeared more affected by neoadjuvant chemotherapy in thymomas with prominent lymphocytic components (WHO types B1 and B2) than in thymomas with a minimal lymphocytic component (types A and B3 thymomas). Similarly, in the study of thymomas after neoadjuvant radiation by Onuki et al., 9 four of five pretreatment type B1 thymomas (80%) were interpreted as type B2 thymoma after treatment. In that study, the change to B2 was attributed to a possible loss of overall lymphocytes. In our study, only three cases showed a relative loss of lymphocytes after neoadjuvant chemotherapy leading to a change in histologic classification. However, these three particular TETs did not show a marked treatment response, with TRGs of 3, 4 and 5. Moreover, the TETs with the least lymphocytes (type B3 thymomas and thymic carcinomas) had an overall better response to treatment. Therefore, in our study, treatment response was not related to the lymphocyte-rich TET and an overall loss of lymphocytes. Furthermore, tumor heterogeneity certainly could explain differences in WHO type between pretreatment and posttreatment specimens given that pretreatment diagnoses were made on small biopsy specimens.
Using RECIST, v1.1, we showed that all thymomas and thymic carcinomas had either a partial response or stable disease in response to neoadjuvant treatment. Although half of the patients with thymic carcinomas (seven of 14 [50%]) had a partial response, most of those thymomas (six of 10 [60%]) had stable disease. As in our study, a recent phase II study of locally advanced thymomas (n ¼ 14) and thymic carcinomas (n ¼ 8) by Korst et al. 10 showed that 48% and 52% of patients had partial and stable radiographic response, respectively. Likewise, in a study of 10 locally advanced TETs that also were treated with neoadjuvant chemoradiation followed by surgery, Wright et al. 11 showed that 40% and 60% had partial response or stable radiographic disease, respectively.
In our study, in which tumor longest diameter was used as an objective radiologic measurement of tumor size before and after treatment, all thymomas and thymic carcinomas had a reduction in tumor size. Similarly, almost all tumors had a reduction in tumor volume. Overall, thymic carcinomas showed the largest reduction in tumor size, as measured by either tumor longest diameter or tumor volume; however, the overall reduction was not significantly different from that shown by thymomas. There was a strong correlation between reduction in tumor longest diameter and tumor volume as measured on CT images, suggesting that both measurement techniques perform equally.
We did not observe tumor progression or complete radiologic response in any TET. The lack of complete radiologic response may be explained at least in part by the prominent fibrosis seen in these tumors after neoadjuvant therapy, including in cases that had complete pathologic response.
In our study, morphologic response to neoadjuvant treatment correlated with radiologic response. All patients with a complete pathologic response had a partial radiologic response whereas all patients who did not show any pathologic response had stable radiologic disease. Moreover, tumor longest diameter and tumor volume were useful to predict pathologic response of TETs to neoadjuvant therapy. For instance, partial radiologic response correlated with better pathologic treatment response, including lower TRG and lower percent viable tumor. Furthermore, larger reduction in tumor longest diameter and tumor volume on posttreatment CT scan was also associated with more pathologic treatment response, including lower TRG and lower percent viable tumor. Moreover, TRG and percent viable tumor correlated with percent change in tumor longest diameter and volume. Finally, radiologic change in tumor longest diameter and volume did reasonably discriminate between tumors with a TRG of 3 to 5 and those with a TRG of 1 or 2. For practical purposes, if imaging studies revealed a partial response, the TRG ranged between one and three in thymic carcinomas and between two and four in thymomas, respectively. In cases in which imaging studies showed stable disease, the TRG ranged between two and five in thymic carcinomas and between three and five in thymomas, respectively. Given that radiologic and pathologic response correlated with one another, radiologic response might become useful to predict pathologic response. However, because imaging studies showed only partial response in cases with complete pathologic response, multidisciplinary measures are currently needed to identify these patients.
Most studies of TETs find that complete resection has prognostic significance. [1] [2] [3] [4] We confirmed this finding, showing that patients who underwent complete resection of TETs had significantly better OS than patients who underwent incomplete resection or biopsy only. Pretreatment therapy may be helpful to reach resectability. In our study, pretreatment therapy led to a 71.4% (for thymomas) and 61.9% (for thymic carcinomas) complete resection rate. Although an overall complete resection rate of 67.3% was achieved, there was no difference in complete resection rate based on treatment modality type (chemotherapy versus radiation versus chemoradiation). The complete resection rate in our study was similar to that in other studies. For instance the study by Korst et al. 10 showed a 77% complete resection rate in 14 thymomas and eight thymic carcinomas and Wright et al. 11 achieved a 80% complete resection rate in nine thymomas and one thymic carcinoma after chemoradiation therapy. Four studies encompassing seven to 25 patients with thymoma who underwent neoadjuvant chemotherapy followed by surgery showed a complete resection rate between 57% and 80%. [5] [6] [7] [8] A study of 21 patients with stage III thymomas that were preoperatively treated with radiation achieved a 90% complete resection rate. 9 There are challenges in the study of the pathologic treatment response of TETs. First, the histologic classification of posttreatment TETs was difficult because the histologic type might be biased on account of treatment effect as well as heterogeneity of TETs and interobserver variability, which we have shown previously. 19 Second, differences in neoadjuvant treatment occurred not only between studies but also within studies, including ours. Given the rarity of the tumor, these differences were unavoidable because to achieve a larger number of cases, these had to be collected over many years. Third, there was histologic overlap between possibly treatment-related morphologic findings and findings in untreated TETs. For instance, in some cases it was difficult to distinguish between treatment-related fibrosis and fibrous bands of thymomas. Necrosis might have been present even before treatment; in fact, some thymomas can be largely necrotic. In addition, carcinomas can always be associated with areas of necrosis. Fourth, the number of our patients, even though they had been accrued over almost one century, was too small to correlate TRG with outcome.
In conclusion, our proposed histologic TRG for TETs appears reproducible and correlates with radiologic response. Radiologic response is useful to predict pathologic response. Our findings need to be validated by larger, probably multi-institutional, studies to achieve a large number of cases given the relative low incidence of these tumors. Moreover, larger studies are necessary to identify whether TRG can predict outcome.
